Leerink Partners analyst Faisal Khurshid reiterated a Buy rating on Immunic (IMUX – Research Report) on November 7 and set a price target ...

Multiple sclerosis (MS) is characterized by chronic inflammation ... Current treatment guidelines recommend starting disease-modifying therapies soon after disease onset. These treatments have ...

Multiple sclerosis is not merely a market—it’s a debilitating ... or is there a vested interest in maintaining a long-term demand for treatments that address symptoms rather than the root of the ...

A chronic and progressive neurological condition that affects millions across the world, multiple sclerosis (MS) can be a ...

The results from a new study of the multi-kinase inhibitor fexagratinib in mouse models are raising hopes that the therapy ...

In July, our management team was strengthened with the addition of Jason Tardio, as President and Chief Operating Officer, bringing with him a wealth of experience launching and commercializing ...

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move ...

Doctors weigh in on why patients often receive conflicting diagnoses, and share insights on navigating the complex path to clarity and trust.

The quest to understand and slow disease progression in multiple sclerosis (MS) continued in 2024, with research revealing ...

Many types of medications, including over-the-counter (OTC) and prescription drugs, can help relieve joint pain due to ...

The field of geriatric pharmacotherapy is increasingly focused on the challenges of appropriate prescribing and deprescribing and represcribing in older patients. As individuals age, they often ...

In the United States, out-of-pocket (OOP) costs of brand-name medications for neurological disorders increased significantly ...